Nika Pharmaceuticals, Inc. (NIKA) Signed a Consultancy Agreement with MD Global Partners LLC

Rhea-AI Summary

Nika Pharmaceuticals (OTCQB: NIKA) signed a consultancy agreement with MD Global Partners LLC on March 6, 2026. MD Global, a Manhattan-based investment bank, will provide advisory services that may include capital raising support, growth planning, and due diligence on potential transactions.

Management said the advisor's expertise should support expansion when the companys production factory becomes operational and distribution begins.

HENDERSON, Nev., March 06, 2026 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) announces that it has signed a consultancy agreement with MD Global Partners LLC, a leading Manhattan-based investment bank. MD Global will provide NIKA with various services, which may include, but are not limited to assistance in capital raising efforts, growth initiatives, and conducting due diligence on potential transactions.

“As we prepare for the next stages of our development, it is important that we have an advisor with proven track record and expertise”, stated Dimitar Savov, CEO of NIKA. “We expect significant growth once the production factory is operational and distribution begins, so the experience of MD Global Partners will be an important asset to our company. I believe that this is the start of a valuable long-term partnership,” concluded Savov.

About Nika Pharmaceuticals, Inc.

Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA’s goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on www.nikapharmaceuticals.com.

Forward-looking Statement:

This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally are identified by the words “believes,” “estimates,” “projects,” “intends,” “plan,” “can,” “will,” “would,” “expects,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.

CONTACT Clifford Redekop, Secretary
COMPANY Nika Pharmaceuticals, Inc.
PHONE (702)-326-3615
EMAIL info@nikapharmaceuticals.com
WEB www.nikapharmaceuticals.com

FAQ

What did NIKA announce about the consultancy agreement with MD Global Partners on March 6, 2026?

Nika announced it signed a consultancy agreement with MD Global Partners LLC to provide advisory services. According to the company, services may include capital raising assistance, growth initiatives, and due diligence on potential transactions as the company prepares factory production and distribution.

How might the MD Global Partners agreement affect NIKA (OTCQB:NIKA) capital raising efforts?

The agreement could support Nika's capital raising efforts by providing investment banking advisory services. According to the company, MD Global may assist with capital raising and transaction due diligence, which management expects to help as production and distribution ramp up.

What specific services will MD Global Partners provide to NIKA under the consultancy agreement?

MD Global will provide advisory services that may include capital raising, growth planning, and due diligence on potential transactions. According to the company, the list of services is not exhaustive and may encompass other strategic support tied to Nikas development.

Does the NIKA announcement state any timelines or financial terms for the MD Global consultancy?

The announcement does not disclose specific timelines or financial terms for the consultancy agreement. According to the company, the agreement focuses on advisory services to support growth ahead of factory production and distribution, without detailing fees or dates.